Inhibitors of influenza viruses replication

A compound of Formula (IV):

• or a pharmaceutically acceptable salt thereof, wherein:
• X1 is —F, —CF3, —CN, or —CH3;
• X2 is —H, —F, or —Cl;
• Z1 is N or CH;
• Z2 is N or CR0;
• R0 is —H, —F, or —CN;
• R1, R2, and R3 are each independently —CH3, —CH2F, —CF3, —C2H5, —CH2CH2F, or —CH2CF3;
• R4 and R5 are each independently —H;
• Q is —C(O)OR;
• and
• R is —H or C1-4 alkyl.

A pharmaceutical composition comprising a compound of Formula (IV)

• or a pharmaceutically acceptable salt thereof, wherein:
• X1 is —F, —Cl, —CF3, —CN, or —CH3;
• X2 is —H, —F, or —Cl;
• Z1 is N or CH;
• Z2 is N or CR0;
• R0 is —H, —F, or —CN;
• R1, R2, and R3 are each independently —CH3, —CH2F, —CF3, —C2H5, —CH2CH2F, or —CH2CF3;
• R4 and R5 are each independently —H;
• Q is —C(O)OR;
• and
• R is —H or C1-4 alkyl, and
• a pharmaceutically acceptable carrier, adjuvant or vehicle.

A method of preparing a compound of Formula (IV)

• or a pharmaceutically acceptable salt thereof, wherein
• X1 is —F, —Cl, -pCF3, —CN, or —CH3;
• X2 is —H, —F, or —Cl;
• Z1 is N or CH;
• Z2 is N or CR0;
• R0 is —H, —F, or —CN;
• R1, R2, and R3 are each independently —CH3, —CH2F, —CF3, —C2H5, —CH2CH2F, or —CH2CF3;
• R4 and R5 are each independently —H;
• Q is —C(O)OR;
• and
• R is —H or C1-4 alkyl,
• comprising the steps of:
• (i) reacting a compound having the formula
• wherein L2 is a halogen, with compound B
• wherein G is trityl, to form a compound
• and
• (ii) deprotecting the G group of the compound synthesized in step (i) under suitable conditions to form a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.